TY - JOUR A1 - Müller, Patrick A1 - Meta, Mergim A1 - Meidner, Jan Laurenz A1 - Schwickert, Marvin A1 - Meyr, Jessica A1 - Schwickert, Kevin A1 - Kersten, Christian A1 - Zimmer, Collin A1 - Hammerschmidt, Stefan Josef A1 - Frey, Ariane A1 - Lahu, Albin A1 - de la Hoz-Rodríguez, Sergio A1 - Agost-Beltrán, Laura A1 - Rodríguez, Santiago A1 - Diemer, Kira A1 - Neumann, Wilhelm A1 - Gonzàlez, Florenci V. A1 - Engels, Bernd A1 - Schirmeister, Tanja T1 - Investigation of the compatibility between warheads and peptidomimetic sequences of protease inhibitors — a comprehensive reactivity and selectivity study JF - International Journal of Molecular Sciences N2 - Covalent peptidomimetic protease inhibitors have gained a lot of attention in drug development in recent years. They are designed to covalently bind the catalytically active amino acids through electrophilic groups called warheads. Covalent inhibition has an advantage in terms of pharmacodynamic properties but can also bear toxicity risks due to non-selective off-target protein binding. Therefore, the right combination of a reactive warhead with a well-suited peptidomimetic sequence is of great importance. Herein, the selectivities of well-known warheads combined with peptidomimetic sequences suited for five different proteases were investigated, highlighting the impact of both structure parts (warhead and peptidomimetic sequence) for affinity and selectivity. Molecular docking gave insights into the predicted binding modes of the inhibitors inside the binding pockets of the different enzymes. Moreover, the warheads were investigated by NMR and LC-MS reactivity assays against serine/threonine and cysteine nucleophile models, as well as by quantum mechanics simulations. KW - covalent inhibitors KW - in vitro study KW - protease inhibitors KW - peptidomimetic sequence KW - warhead KW - reactivity and selectivity study Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-313596 SN - 1422-0067 VL - 24 IS - 8 ER - TY - JOUR A1 - Geiger, Nina A1 - Diesendorf, Viktoria A1 - Roll, Valeria A1 - König, Eva-Maria A1 - Obernolte, Helena A1 - Sewald, Katherina A1 - Breidenbach, Julian A1 - Pillaiyar, Thanigaimalai A1 - Gütschow, Michael A1 - Müller, Christa E. A1 - Bodem, Jochen T1 - Cell type-specific anti-viral effects of novel SARS-CoV-2 main protease inhibitors JF - International Journal of Molecular Sciences N2 - Recently, we have described novel pyridyl indole esters and peptidomimetics as potent inhibitors of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) main protease. Here, we analysed the impact of these compounds on viral replication. It has been shown that some antivirals against SARS-CoV-2 act in a cell line-specific way. Thus, the compounds were tested in Vero, Huh-7, and Calu-3 cells. We showed that the protease inhibitors at 30 µM suppress viral replication by up to 5 orders of magnitude in Huh-7 cells, while in Calu-3 cells, suppression by 2 orders of magnitude was achieved. Three pyridin-3-yl indole-carboxylates inhibited viral replication in all cell lines, indicating that they might repress viral replication in human tissue as well. Thus, we investigated three compounds in human precision-cut lung slices and observed donor-dependent antiviral activity in this patient-near system. Our results provide evidence that even direct-acting antivirals may act in a cell line-specific manner. KW - SARS-CoV-2 KW - protease inhibitors KW - cell line specificity pyridyl indole carboxylates KW - azapeptide nitriles KW - peptidomimetics Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-304034 SN - 1422-0067 VL - 24 IS - 4 ER - TY - JOUR A1 - Welker, Armin A1 - Kersten, Christian A1 - Müller, Christin A1 - Madhugiri, Ramakanth A1 - Zimmer, Collin A1 - Müller, Patrick A1 - Zimmermann, Robert A1 - Hammerschmidt, Stefan A1 - Maus, Hannah A1 - Ziebuhr, John A1 - Sotriffer, Christoph A1 - Schirmeister, Tanja T1 - Structure‐Activity Relationships of Benzamides and Isoindolines Designed as SARS‐CoV Protease Inhibitors Effective against SARS‐CoV‐2 JF - ChemMedChem N2 - Inhibition of coronavirus (CoV)‐encoded papain‐like cysteine proteases (PL\(^{pro}\)) represents an attractive strategy to treat infections by these important human pathogens. Herein we report on structure‐activity relationships (SAR) of the noncovalent active‐site directed inhibitor (R)‐5‐amino‐2‐methyl‐N‐(1‐(naphthalen‐1‐yl)ethyl) benzamide (2 b), which is known to bind into the S3 and S4 pockets of the SARS‐CoV PL\(^{pro}\). Moreover, we report the discovery of isoindolines as a new class of potent PL\(^{pro}\) inhibitors. The studies also provide a deeper understanding of the binding modes of this inhibitor class. Importantly, the inhibitors were also confirmed to inhibit SARS‐CoV‐2 replication in cell culture suggesting that, due to the high structural similarities of the target proteases, inhibitors identified against SARS‐CoV PL\(^{pro}\) are valuable starting points for the development of new pan‐coronaviral inhibitors. KW - antiviral agents KW - computational chemistry KW - drug design KW - protease inhibitors KW - structure-activity relationships Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-225700 VL - 16 IS - 2 SP - 340 EP - 354 ER - TY - THES A1 - Wolf, Katarina T1 - Migration of tumor cells and leukocytes in extracellular matrix : proteolytic and nonproteolytic strategies for overcoming tissue barriers T1 - Migration von Tumorzellen und Leukozyten in extrazellulärer Matrix : proteolytische und nicht-proteolytische Strategien zur Überwindung von Gewebsbarrieren N2 - The extracellular matrix within connective tissues represents a structural scaffold as well as a barrier for motile cells, such as invading tumor cells or passenger leukocytes. It remains unclear how different cell types utilize matrix-degrading enzymes for proteolytic migration strategies and, on the other hand, non-proteolytic strategies to overcome 3D fibrillar matrix networks. To monitor cell migration, a 3D collagen model in vitro or the mouse dermis in vivo were used, in combination with time-lapse video-, confocal- or intravital multiphoton-microscopy, and computer-assisted cell tracking. Expression of proteases, including several MMPs, ADAMs, serine proteases and cathepsins, was shown by flow cytometry, Western blot, zymography, and RT-PCR. Protease activity by migrating HT-1080 fibrosarcoma cells resulting in collagenolysis in situ and generation of tube-like matrix defects was detected by three newly developed techniques:(i) quantitative FITC-release from FITC-labelled collagen, (ii) structural alteration of the pyhsical matrix structure (macroscopically and microscopically), and (iii) the visualization of focal in situ cleavage of individual collagen fibers. The results show that highly invasive ollagenolytic cells utilized a spindle-shaped "mesenchymal" migration strategy, which involved beta1 integrindependent interaction with fibers, coclustering of beta1 integrins and matrix metalloproteinases (MMPs) at fiber bundling sites, and the proteolytic generation of a tube-like matrix-defect by MMPs and additional proteases. In contrast to tumor cells, activated T cells migrated through the collagen fiber network by flexible "amoeboid" crawling including a roundish, elliptoid shape and morphological adaptation along collagen fibers, which was independent of collagenase function and fiber degradation. Abrogation of collagenolysis in tumor cells was achieved by a cocktail of broad-spectrum protease inhibitors at non-toxic conditions blocking collagenolysis by up to 95%. While in T cells protease inhibition induced neither morphodynamic changes nor reduced migration rates, in tumor cells a time-dependent conversion was obtained from proteolytic mesenchymal to non-proteolytic amoeboid migration in collagen lattices in vitro as well as the mouse dermis in vivo monitored by intravital microscopy. Tumor cells vigorously squeezed through matrix gaps and formed constriction rings in regions of narrow space, while the matrix structure remained intact. MMPs were excluded from fiber binding sites and beta1 integrin distribution was non-clustered linear. Besides for fibrosarcoma cells, this mesenchymal-toameboid transition (MAT) was confirmed for epithelial MDA-MB-231 breast carcinoma cells. In conclusion, cells of different origin exhibit significant diversity as well as plasticity of protease function in migration. In tumor cells, MAT could respresent a functionally important cellular and molecular escape pathway in tumor invasion and migration. N2 - Die extrazelluläre Matrix (EZM) des Bindegewebes stellt sowohl ein strukturelles Gerüst als auch eine Barriere für migrierende Zellen dar, wie z.B. invadierende Tumorzellen oder zirkulierende Leukozyten. Es ist bisher unklar, wie diese verschiedenen Zelltypen matrix-degradierende Enzyme für eine proteolytische Migrationsstrategie benutzen bzw. ob und wie sie ohne deren Hilfe durch das Gewebe gelangen. Um Zellmigration in EZM zu untersuchen, wurde ein dreidimensionales Kollagenmodell in vitro wie auch Maus-Dermis in vivo eingesetzt und Zellmigration mittels Zeitraffer-Video-, Konfokal- und Multiphoton-Mikroskopie sowie computer-gestützter Zelltracking-Analyse dargestellt. Expression von Proteasen verschiedener Klassen, wie der MMPs, ADAMs, Serinproteasen und Cathepsine, wurde mittels Durchfluss-Zytometrie, Western blot, Zymographie oder RT-PCR detektiert. Gegen Kollagen gerichtete zelluläre Protease-Aktivität wurde mit Hilfe drei neu entwickelter Techniken dargestellt: (i)quantitative Messung von löslichem FITC aus FITC-markiertem fibrillären Kollagen, (ii) mikro-und makroskopische Reorganisation der physikalischen Matrix-Struktur, und (iii) Visualisierung der Topologie fokaler Degradation von Matrixfasern. Die Ergebnisse zeigen, dass hochinvasive spindelförmige HT-1080 Fibrosarkomzellen eine sogenannte "mesenchymale" Migrationsstrategie mit folgenden Charakteristika entwickelten: (i) beta1 Integrin-abhängige Interaktion mit Kollagenfasern, (ii) das "Co-clustering" von beta1 Integrinen und Matrix-Metalloproteinasen an Faserzugstellen und (iii) eine röhrenförmige, durch Proteasen verursachte Matrixdefektbildung. Im Gegensatz zu proteolytischen Tumorzellen migrierten T-Zellen rundlich-elliptoid mittels flexibler Morphodynamik, ähnlich wie Amöben, durch das Kollagennetzwerk und orientierten sich entlang Kollagenfasern, wobei sie keine biochemisch und strukturell detektierbare Faserdegradation zeigten. Um Tumorzell-vermittelte Kollagenolyse zu hemmen, wurde ein Cocktail, bestehend aus Breitspektrum-Protease-Inhibitioren, etabliert, der die Kollagenolyse unter nicht-toxischen Bedingungen um bis zu 98% blockierte. Während in T-Zellen keine morphodynamischen Veränderungen detektiert wurden, entwickelten Tumorzellen eine Verschiebung von proteolytisch mesenchymaler zu unverminderter nicht-proteolytisch amöboider Migration (mesenchymale-amöboide Transition - MAT) aus, sowohl in Kollagenmatrices in vitro als auch in Maus-Dermis in vivo, dargestellt mittels Intravital-Multiphoton-Mikroskopie. Die Tumorzellen "quetschten" sich dabei durch Lücken in der Matrix und bildeten sogenannte Konstriktionsringe aus, während die Matrixstruktur intakt blieb. MMPs lokalisierten nicht mehr an Faser-Kontakstellen auf der Zelloberfläche, und beta1 Integrine lagen nicht mehr geclustert vor. Neben HT-1080 Fibrosarkomzellen wurde MAT auch für MDA-MB-231 Brustkrebszellen epithelialer Herkunft nach Protease-Blockade detektiert. Somit entwickeln migrierende Zellen verschiedener Herkunft eine signifikante Diversität wie auch Plastizität bei der Migration durch EZM aus, resultierend aus der Funktionalität von Matrix-Proteasen. In Tumorzellen könnte MAT einen funktionell wichtigen zellulären und molekularen Anpassungsmechanismus für die Tumorinvasion und -migration darstellen. KW - Zellmigration KW - Grundsubstanz KW - Tumorzelle KW - Leukozyt KW - Zellmigration KW - Invasion KW - Karzinomzellen KW - Leukozyten KW - Matrixproteasen KW - Kollagenasen KW - Proteaseinhibitoren KW - cell migration KW - invasion KW - carcinoma cells KW - leukozytes KW - matrix proteases KW - collagenases KW - protease inhibitors Y1 - 2002 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-5670 ER -